Assignee
MISSION THERAPEUTICS LTD
GB·31 granted patents·9 pending applications·46 citations·filing 2015–2022
Top patents by PatentIndex Score
40 records- 0194US9926307B2CompoundsMISSION THERAPEUTICS LTD·Filed 2015·Granted Mar 27, 2018·14 cites·16 claims
- 0293US10343992B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2016·Granted Jul 9, 2019·7 cites·2 claims
- 0392US10689345B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2019·Granted Jun 23, 2020·4 cites·14 claims
- 0489US10392380B2CompoundsMISSION THERAPEUTICS LTD·Filed 2018·Granted Aug 27, 2019·6 cites·17 claims
- 0587US11130748B2CompoundsMISSION THERAPEUTICS LTD·Filed 2016·Granted Sep 28, 2021·3 cites·12 claims
- 0687US10774078B2CompoundsMISSION THERAPEUTICS LTD·Filed 2019·Granted Sep 15, 2020·2 cites·10 claims
- 0786US11472798B2CompoundsMISSION THERAPEUTICS LTD·Filed 2020·Granted Oct 18, 2022·1 cites·11 claims
- 0885US10640498B2CompoundsMISSION THERAPEUTICS LTD·Filed 2017·Granted May 5, 2020·6 cites·17 claims
- 0983US11390584B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2020·Granted Jul 19, 2022·1 cites·14 claims
- 1081US11993595B2CompoundsMISSION THERAPEUTICS LTD·Filed 2022·Granted May 28, 2024·0 cites·10 claims
- 1178US2022251041A11-cyano-pyrrolidine compounds as usp30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 1273US10669234B2Cyanopyrrolidines as dub inhibitors for the treatment of cancerMISSION THERAPEUTICS LTD·Filed 2016·Granted Jun 2, 2020·1 cites·15 claims
- 1372US10683269B22-cyanoisoindoline derivatives for treating cancerMISSION THERAPEUTICS LTD·Filed 2017·Granted Jun 16, 2020·1 cites·15 claims
- 1470US11066365B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2019·Granted Jul 20, 2021·0 cites·14 claims
- 1570US11053198B21-cyano-pyrrolidine compounds as USP30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2019·Granted Jul 6, 2021·0 cites·4 claims
- 1670US2022106315A1Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitorsMISSION THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1768US11958833B2CompoundsMISSION THERAPEUTICS LTD·Filed 2021·Granted Apr 16, 2024·0 cites·14 claims
- 1868US11945797B21-cyano-pyrrolidine derivatives as dub inhibitorsMISSION THERAPEUTICS LTD·Filed 2022·Granted Apr 2, 2024·0 cites·15 claims
- 1966US11236092B2Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitorsMISSION THERAPEUTICS LTD·Filed 2020·Granted Feb 1, 2022·0 cites·10 claims
- 2062US2025034122A1Substituted n-cyanopyrrolidines with activity as usp30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 2160US11319287B2Cyanopyrrolidines as dub inhibitors for the treatment of cancerMISSION THERAPEUTICS LTD·Filed 2020·Granted May 3, 2022·0 cites·15 claims
- 2254US2023219939A1N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunctionMISSION THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2354US2023312580A11-(5-(2-cyanopyridin-4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyr role-5(1h)-carbonitrile as usp30 inhibitor for use in the treatment of mitochondrial dysfunction, cancer and fibrosisMISSION THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2454US2023303547A1N-cyanopyrrolidines with activity as usp30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2553US10654853B2Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitorsMISSION THERAPEUTICS LTD·Filed 2017·Granted May 19, 2020·0 cites·10 claims
- 2653US2023119013A1N-cyanopyrrolidines with activity as usp30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 2750US2022315572A1Substituted cyanopyrrolidines with activity as usp30 inhibitorsMISSION THERAPEUTICS LTD·Filed 2020·Application pending·0 cites
- 2848US11352339B21-cyano-pyrrolidine derivatives as DUB inhibitorsMISSION THERAPEUTICS LTD·Filed 2017·Granted Jun 7, 2022·0 cites·15 claims
- 2946US11414402B2Sulfonamide-substituted cyanopyrrolidines with activity as DUB inhibitorsMISSION THERAPEUTICS LTD·Filed 2018·Granted Aug 16, 2022·0 cites·14 claims
- 3046US10927110B2Cyano-subtituted heterocycles with activity as inhibitors of USP30MISSION THERAPEUTICS LTD·Filed 2017·Granted Feb 23, 2021·0 cites·16 claims
- 3144US11059809B2Substituted cyanopyrrolidines with activity as DUB inhibitorsMISSION THERAPEUTICS LTD·Filed 2018·Granted Jul 13, 2021·0 cites·16 claims
- 3243US11370784B2Cyano-substituted heterocycles with activity as inhibitors of USP30MISSION THERAPEUTICS LTD·Filed 2017·Granted Jun 28, 2022·0 cites·14 claims
- 3343US10690656B2Methods of screening and treatment with USP4 inhibitorsMISSION THERAPEUTICS LTD·Filed 2016·Granted Jun 23, 2020·0 cites·9 claims
- 3442US11084821B2Cyanopyrrolidine derivatives with activity as inhibitors of USP30MISSION THERAPEUTICS LTD·Filed 2017·Granted Aug 10, 2021·0 cites·19 claims
- 3541US11014912B2Cyanopyrrolidine derivatives with activity as inhibitors of USP30MISSION THERAPEUTICS LTD·Filed 2017·Granted May 25, 2021·0 cites·17 claims
- 3641US2021002262A1Cyanopyrrolidines as usp30 inhibitors and fibrosis treatmentMISSION THERAPEUTICS LTD·Filed 2019·Application pending·0 cites
- 3740US11306096B24,6 dihydropyrrolo [3,4-C] pyrazole-5 (1H)-carbonitrile derivates for treating cancerMISSION THERAPEUTICS LTD·Filed 2017·Granted Apr 19, 2022·0 cites·11 claims
- 3840US11091488B21-cyano-pyrrolidine derivatives as inhibitors of USP30MISSION THERAPEUTICS LTD·Filed 2016·Granted Aug 17, 2021·0 cites·18 claims
- 3940US10590075B2Cyanopyrrolidine derivatives as inhibitors for DUBsMISSION THERAPEUTICS LTD·Filed 2016·Granted Mar 17, 2020·0 cites·18 claims
- 4035US10527610B2Methodologies for measuring isopeptidase activity in biological samples in a high throughput mannerMISSION THERAPEUTICS LTD·Filed 2015·Granted Jan 7, 2020·0 cites·22 claims
Join the waitlist — get patent alerts
Get an alert when MISSION THERAPEUTICS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →